a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR
| Registry | NCT03284827, acronym ADAPT-TAVR |
|---|---|
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: none, prevention |
| Enrollment | 235 (Actual) |
| Sponsor | Duk-Woo Park, MD (Other); collaborators: CardioVascular Research Foundation, Korea, Daiichi Sankyo Korea Co., Ltd. |
| Conditions | Aortic Valve Stenosis |
| Interventions | NOAC, DAPT (Drug) |
| Dates | start 2018-03-15, primary completion 2021-10-26, completion 2021-11-05, first posted 2017-09-15, last updated 2021-11-08 |
| Locations | 5 sites in Hong Kong, South Korea, Taiwan |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Aortic Valve Stenosis All trials of NOAC All trials of DAPT
This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs. dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac CT imaging) and cerebral embolization (documented with brainDiffusion-weighted (DW) magnetic resonance (MR) imaging) in patients without an absolute indication for chronic oral anticoagulation (OAC) after successful transcatheter aortic valve replacement(TAVR).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NOAC | Experimental | Drug: NOAC | 60 mg once daily |
| DAPT | Active comparator | Drug: DAPT | clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) |
Sex: All, ages: 19 Years to any
Inclusion Criteria:
1. Patients 19 years of age or older with successful TAVR procedure
* either native valve or valve-in-valve with any approved/marketed device
* A successful TAVR is defined as device success according to the VARC-2 criteria:
1. correct positioning of a single prosthetic heart valve into the proper anatomical location AND
2. Intended performance of the prosthetic heart valve (no prosthesis- patient mismatch* and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, no moderate or severe prosthetic valve regurgitation AND
3. absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure.
2. Patients who voluntarily participated in the written agreement
Exclusion Criteria:
1. Any atrial fibrillation with an indication for chronic OAC.
2. An ongoing indication for OAC or any other indication for continued treatment with any OAC
3. Any ongoing indication for DAPT (recent acute coronary syndrome or PCI within 12 months)
4. Planned coronary or vascular intervention or major surgery
5. Clinically significant bleeding patients
6. The risk of bleeding increased due to the following reasons at the time of TAVR procedure, i. history of gastrointestinal ulcers within 1 month ii. Malignant tumor with high risk of bleeding iii. Brain or spinal cord injury within 1 month iv. History of intracranial or intracerebral hemorrhage within 12 months v. Esophageal varices vi. Arteriovenous malformation vii. Vascular aneurysms viii. Spinal cord vascular abnormalities or intracerebral vascular abnormalities ix. Active bleeding x. Hemoglobin level <7.0 g/dL or platelet count ≤ 50,000 / mm3 xi. History of major surgery within 1 month
7. Clinically overt stroke within the last 3 months
8. Moderate and severe hepatic impairment, and any hepatic disease associated with coagulopathy
9. Severe renal impairment (CrCl by Cockcroft-Gault equation<15 mL/min per 1.73 m2), chronic dialysis, or post-TAVR unresolved acute kidney injury
10. Terminal illness with life expectancy <6 months
11. Hypersensitivity to the main component or constituents of Edoxaban
12. Severe hypertensive patient
13. Patient who received prosthetic heart valve replacement for which anticoagulant therapy is essential
14. Moderate to severe mitral stenosis
15. Pulmonary embolism requiring thrombolysis or pulmonary embolectomy
16. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
17. Pregnancy test results are positive (all pregnant women should undergo urinary human chorionic gonadotropin (hCG) testing within 7 days prior to screening and / or randomization) or during pregnancy or lactation
18. Genetic problem with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
19. History of hypersensitivity to Edoxaban, Aspirin or clopidogrel
20. Current or history of Aspirin- or NSAIDs-induced asthma
21. Hemophilia
22. Patients who are using Methotrexate at doses of 15mg or more per week
23. Patients who have unsuitable condition to undergo Brain MRI(Magnetic resonance imaging) and/or Cardiac CT(computed tomography) (e.g., tremor from Parkinson's disease). This is at the discretion of investigators.| Facility | City | Country | Status |
|---|---|---|---|
| Queen Mary Hospital | Hong Kong | Hong Kong | |
| Asan Medical Center | Seoul, Songpa-gu | South Korea | |
| Bundang CHA Hospital | Seongnam | South Korea | |
| Cheng Hsin General Hospital | Taipei | Taiwan | |
| National Taiwan University Hospital | Taipei | Taiwan |